In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection.
In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. by Fernandez-Silva F, Lackner M, Capilla J, Mayayo E, Sutton D, Castanheira M, Fothergill AW, Lass-Florl C and Guarro J published in Antimicrob. Agents Chemother. 2014; 58 (7): 3646-3649
Revised reference broth microdilution method for testing telavancin: Effect on MIC results and correlation with other testing methodologies.
Revised reference broth microdilution method for testing telavancin: Effect on MIC results and correlation with other testing methodologies. by Farrell DJ, Mendes RE, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (9): 5547-5551
Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. by Castanheira M, Messer SA, Jones RN, Farrell DJ and Pfaller MA published in Int. J. Antimicrob. Agents. 2014; 44 (4): 320-326
Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying ß-lactamases prevalent in the United States.
Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying ß-lactamases prevalent in the United States. by Castanheira M, Williams G, Jones RN and Sader HS published in Microb. Drug Res. 2014; 20 (5): 436-440
Quality control MIC ranges for telavancin with application of a revised CLSI reference broth microdilution method.
Quality control MIC ranges for telavancin with application of a revised CLSI reference broth microdilution method. by Ross JE, Mendes RE and Jones RN published in J. Clin. Microbiol. 2014; 52 (9): 3399-3401
Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values by Pfaller MA, Castanheira M, Messer SA, Rhomberg PR, Dietrich RR and Jones RN published in Mycopathologia 2014; 178 (1-2): 1-9
In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011).
In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). by Flamm RK, Jones RN and Sader HS published in J. Global Antimicrob. Res. 2014; 2 (2): 183-189
Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: An epidemiological and structural perspective.
Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: An epidemiological and structural perspective. by Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP and Lahiri SD published in J. Antimicrob. Chemother. 2014; 69 (8): 2065-2075
Ceftaroline activity tested against bacterial isolates from pediatric patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation program for the United States (2011-2012).
Ceftaroline activity tested against bacterial isolates from pediatric patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation program for the United States (2011-2012). by Sader HS, Mendes RE, Farrell DJ, Flamm RK and Jones RN published in Pediatr. Infect. Dis. J. 2014; 33 (8): 837-842
Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.
Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (7): 3882-3888
Oritavancin activity against Staphylococcus aureus causing invasive infections in USA and European hospitals. A five-year international surveillance program.
Oritavancin activity against Staphylococcus aureus causing invasive infections in USA and European hospitals. A five-year international surveillance program. by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (5): 2921-2924
Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011).
Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). by Flamm RK, Sader HS and Jones RN published in Braz. J. Infect. Dis. 2014; 18 (2): 187-195
Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: Results from the AWARE Program, 2009-2011.
Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: Results from the AWARE Program, 2009-2011. by Flamm RK, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 437-442
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal, and urinary tract infections in United States medical centers (2012).
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal, and urinary tract infections in United States medical centers (2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1589-1598
Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).
Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 449-456
Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012).
Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). by Farrell DJ, Sader HS, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (6): 533-539
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to daptomycin, linezolid, vancomycin and strains with defined SCCmec types.
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to daptomycin, linezolid, vancomycin and strains with defined SCCmec types. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 323-327
Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.
Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. by Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Florl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J and Turnidge J published in Antimicrob. Agents Chemother. 2014; 58 (4): 2006-2012
Detection of NDM-1-producing Enterobacteriaceae in Romania: Report of the SENTRY Antimicrobial Surveillance Program.
Detection of NDM-1-producing Enterobacteriaceae in Romania: Report of the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Flonta M, Jones RN and Castanheira M published in J. Med. Microbiol. 2014; 63 (Pt 3): 483-484
Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel.
Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. by Castanheira M, Jones RN and Sader HS published in J. Chemother. 2014; 26 (4): 202-210
Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-2011 in 14 European and Mediterranean countries.
Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-2011 in 14 European and Mediterranean countries. by Castanheira M, Deshpande LM, Costello A, Davies TA and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (7): 1804-1814
Frequency of occurrence and antimicrobial susceptibility of gram-negative bacteremia isolates in patients with urinary tract infection: Results from United States and European hospitals (2009-2011).
Frequency of occurrence and antimicrobial susceptibility of gram-negative bacteremia isolates in patients with urinary tract infection: Results from United States and European hospitals (2009-2011). by Sader HS, Flamm RK and Jones RN published in J. Chemother. 2014; 26 (3): 133-138
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized with pneumonia in United States and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized with pneumonia in United States and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 328-334
Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.
Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. by Mendes RE, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1579-1581
Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: Report of linezolid activity over 9 years (2004 – 2012).
Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: Report of linezolid activity over 9 years (2004 – 2012). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in J. Antimicrob. Chemother. 2014; 69 (6): 1582-1588
Post ß-lactamase inhibitor effect of tazobactam in combination with ceftolozane and tested against ESBL-producing strains.
Post ß-lactamase inhibitor effect of tazobactam in combination with ceftolozane and tested against ESBL-producing strains. by Sader HS, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2434-2437
Ceftaroline activity tested against uncommonly isolated gram-positive pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2008- 2011).
Ceftaroline activity tested against uncommonly isolated gram-positive pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2008- 2011). by Sader HS, Jones RN, Stilwell MG and Flamm RK published in Int. J. Antimicrob. Agents. 2014; 43 (3): 284-286
Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).
Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2274-2280
Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida using CLSI methods and interpretive criteria.
Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida using CLSI methods and interpretive criteria. by Pfaller MA, Messer SA, Diekema DJ, Jones RN and Castanheira M published in J. Clin. Microbiol. 2014; 52 (1): 108-114
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). by Pfaller MA, Flamm RK, Sader HS and Jones RN published in Diag. Microbiol. Infect. Dis 2014; 78 (4): 422-428
Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012.
Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012. by Rennie RP and Jones RN published in Can. J. Infect. Dis. Med. Microbiol. 2014; 25 (5): 285-287
Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011.
Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. by Pfaller MA, Jones RN and Castanheira M published in Mycoses 2014; 57 (10): 602-611
Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).
Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 80 (3): 233-238
Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.
Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. by Flamm RK, Stone GG, Sader HS, Jones RN and Nichols WW published in J. Chemother. 2014; 26 (6): 333-338
Mutation-driven ß-lactam resistance mechanisms among contemporary ceftazidime non-susceptible Pseudomonas aeruginosa isolates from USA hospitals.
Mutation-driven ß-lactam resistance mechanisms among contemporary ceftazidime non-susceptible Pseudomonas aeruginosa isolates from USA hospitals. by Castanheira M, Mills JC, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (11): 6844-6850
Update on Acinetobacter species: Mechanisms of antimicrobial resistances and contemporary in vitro activity of minocycline and other treatment options.
Update on Acinetobacter species: Mechanisms of antimicrobial resistances and contemporary in vitro activity of minocycline and other treatment options. by Castanheira M, Mendes RE and Jones RN published in Clin. Infect. Dis. 2014; 59 (Suppl 6): S367-373
Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean: Two novel beta-lactamases (GES-22 and VIM-35) were detected.
Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean: Two novel beta-lactamases (GES-22 and VIM-35) were detected. by Castanheira M, Costello SE, Woosley LN, Deshpande LM, Davies TA and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (12): 7358-7366
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. by VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG published in Antimicrob. Agents Chemother. 2014; 58 (10): 6024-6031
Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.
Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. by Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A, Fuller J, Gonzalez GM, Guarro J, Lass-Florl C, Lockhart SR and Martin-Mazuelos published in Antimicrob. Agents Chemother. 2014; 58 (2): 916-922
Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States 2014.
Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States 2014. by Mendes RE, Flamm RK, Hogan PA, Ross JE and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (2): 1243-1247
Resistance surveillance program report for selected European nations (2011).
Resistance surveillance program report for selected European nations (2011). by Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 429-436
Retrospective molecular analysis of DIM-1 metallo-ß-lactamase discovered in Pseudomonas stutzeri from India in 2000.
Retrospective molecular analysis of DIM-1 metallo-ß-lactamase discovered in Pseudomonas stutzeri from India in 2000. by Deshpande LM, Jones RN, Woosley LN and Castanheira M published in Antimicrob. Agents Chemother. 2014; 58 (1): 596-598
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. by Castanheira M, Woosley LN, Messer SA, Diekema DJ, Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2014; 58 (1): 577-580
Contemporary diversity of ß-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent ß-lactamase groups.
Contemporary diversity of ß-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent ß-lactamase groups. by Castanheira M, Farrell SE, Krause KM, Jones RN and Sader HS published in Antimicrob. Agents Chemother. 2014; 58 (2): 833-838
Activity of Ceftazidime-Avibactam Tested Against Contemporary (2012) Pathogens from Urinary Tract and Intraabdominal Infections from Patients in the USA
Activity of Ceftazidime-Avibactam Tested Against Contemporary (2012) Pathogens from Urinary Tract and Intraabdominal Infections from Patients in the USA, Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA
Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2012: Regional Activity of Linezolid and Comparator Compounds
Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2012: Regional Activity of Linezolid and Comparator Compounds, Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA
Antimicrobial Activity of Ceftaroline and Comparator Agents Tested Against Bacterial Isolates from Patients with Bacteremia in United States Medical Centers (2012)
Antimicrobial Activity of Ceftaroline and Comparator Agents Tested Against Bacterial Isolates from Patients with Bacteremia in United States Medical Centers (2012), Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA
Antimicrobial Activity of Ceftaroline Tested against Contemporary (2012) Bacteria Isolated from Community-Acquired Respiratory Tract Infections, Including Oxacillin-resistant S. aureus
Antimicrobial Activity of Ceftaroline Tested against Contemporary (2012) Bacteria Isolated from Community-Acquired Respiratory Tract Infections, Including Oxacillin-resistant S. aureus, Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA
Antimicrobial Activity of Ceftaroline Tested against Multidrug Resistant (MDR) Streptococcus pneumoniae in the USA (2009-2012)
Antimicrobial Activity of Ceftaroline Tested against Multidrug Resistant (MDR) Streptococcus pneumoniae in the USA (2009-2012), Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA
Serotype distribution of Streptococcus pneumoniae recovered principally from non-sterile sites in patients aged =18 years in the US (2009-2011)
Serotype distribution of Streptococcus pneumoniae recovered principally from non-sterile sites in patients aged =18 years in the US (2009-2011), Lead author: Hollingsworth RC, presented at ID Week, October 2 – 6, 2013, San Francisco, CA
